Search Page

1

Cite

Share

Androgen receptor signaling in prostate cancer.

Culig Z, Santer FR. Culig Z, et al. Among authors: santer fr. Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27. doi: 10.1007/s10555-013-9474-0. Cancer Metastasis Rev. 2014. PMID: 24384911 Review.

Cite

Share

2

Cite

Share

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E. Navone NM, et al. Among authors: santer fr. Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2. Prostate. 2018. PMID: 30073676

Cite

Share

3

Cite

Share

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z. Handle F, et al. Among authors: santer fr. Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25. Mol Cancer Ther. 2018. PMID: 30254184 Free article.

Cite

Share

4

Cite

Share

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.

Gruber M, Ferrone L, Puhr M, Santer FR, Furlan T, Eder IE, Sampson N, Schäfer G, Handle F, Culig Z. Gruber M, et al. Among authors: santer fr. Endocr Relat Cancer. 2020 Mar;27(3):187-198. doi: 10.1530/ERC-19-0488. Endocr Relat Cancer. 2020. PMID: 31951590 Free PMC article.

Cite

Share

5

Cite

Share

Therapy escape mechanisms in the malignant prostate.

Santer FR, Erb HH, McNeill RV. Santer FR, et al. Semin Cancer Biol. 2015 Dec;35:133-44. doi: 10.1016/j.semcancer.2015.08.005. Epub 2015 Aug 21. Semin Cancer Biol. 2015. PMID: 26299608 Free article. Review.

Cite

Share

6

Cite

Share

Studies on Steroid Receptor Coactivators in Prostate Cancer.

Culig Z, Santer FR. Culig Z, et al. Among authors: santer fr. Methods Mol Biol. 2018;1786:259-262. doi: 10.1007/978-1-4939-7845-8_15. Methods Mol Biol. 2018. PMID: 29786798

Cite

Share

7

Cite

Share

Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D. Urbiola C, et al. Among authors: santer fr. Int J Cancer. 2018 Oct 1;143(7):1786-1796. doi: 10.1002/ijc.31556. Epub 2018 Jul 3. Int J Cancer. 2018. PMID: 29696636 Free PMC article.

Cite

Share

8

Cite

Share

Interleukin-4 induces a CD44_high /CD49b_high PC3 subpopulation with tumor-initiating characteristics.

Erb HHH, Guggenberger F, Santer FR, Culig Z. Erb HHH, et al. Among authors: santer fr. J Cell Biochem. 2018 May;119(5):4103-4112. doi: 10.1002/jcb.26607. Epub 2018 Jan 19. J Cell Biochem. 2018. PMID: 29236307 Free PMC article.

Cite

Share

9

Cite

Share

Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

Culig Z, Santer FR. Culig Z, et al. Among authors: santer fr. World J Urol. 2012 Jun;30(3):297-302. doi: 10.1007/s00345-011-0797-6. Epub 2011 Nov 22. World J Urol. 2012. PMID: 22105110 Review.

Cite

Share

10

Cite

Share

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR. Guggenberger F, et al. Among authors: santer fr. Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. Eur Urol. 2018. PMID: 29914715 No abstract available.

Cite

Share